CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 130 enrolled
Drug / intervention
Mometasone Furoate 50mcg Nasal Spray +1 moredrug
Likely dose
Mometasone Furoate 50mcg Nasal Sprayfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05382494
NCT05382494Phase 4Completed

Efficacy of Intranasal Steroid for Children With Sleep-Disordered Breathing Non-Responsive to Initial Treatment With Intranasal Saline: A Randomized Trial

Murdoch Childrens Research Institute·interventional·Posted May 19, 2022·Updated Sep 30, 2025

In Brief

A Phase 4 clinical trial evaluating Mometasone Furoate 50mcg Nasal Spray and Sodium Chloride 0.9 % Nasal Spray for Sleep Disorder; Breathing-Related and 5 related conditions. Completed, enrolled 130 participants across 2 sites.

Detailed Summary

MIST+ is studying a nasal spray to see if it will reduce the need for surgery for snoring. Children aged 3-12 are invited to take part. Snoring affects up to 10% of children and can cause sleeping problems and concentration or behavioural issues in the daytime. Currently the most common treatment for snoring is surgery to remove the tonsils and/or adenoids, however many children wait a long time to see a specialist. This research is trying to find if nasal sprays can help children with snoring, and whether this can reduce the need for surgery.

Study Details

Timeline

Phase 4CompletedFinished
2023202420252026
First PostedMay 19, 2022
Enrollment StartDec 5, 2022
Primary CompletionJul 17, 2025
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 4.1 years ago

Interventions

Mometasone Furoate 50mcg Nasal Spraydrug

Intranasal steroid (Mometasone Furoate 50mcg) one spray each nostril daily for 6 weeks

Sodium Chloride 0.9 % Nasal Spraydrug

Intranasal saline spray (Sodium Chloride 0.9%) one spray each nostril daily for 6 weeks